title: DR human leukocyte antigens and disease severity in chronic hepatitis C.
abstract: OBJECTIVE
  Immune mechanisms may modulate disease severity in chronic hepatitis C and the DR human leukocyte antigens may affect these mechanisms. Our aims were to evaluate the association between the DR antigens and disease severity at presentation and to seek correlation between these antigens, disease severity and autoantibodies in this condition.
  
  
  METHODS
  Sixty-four patients were assessed prospectively and classified as having mild, moderate and severe disease by clinical, laboratory and histologic criteria. Fourteen DR antigens were determined by restriction fragment length polymorphism or polymerase chain reaction-sequence specific primers. Eighty normal subjects were typed in a similar fashion.
  
  
  RESULTS
  Patients with mild (16), moderate (32) and severe (16) disease at presentation were indistinguishable from each other and from normal subjects by the frequencies of each DR antigen. Subsets of patients with different laboratory and histological findings had DR frequencies comparable to those without these findings and to those of normal subjects. Patients with autoantibodies and/or concurrent immunologic diseases had mild (19% versus 32%, p = 0.4), moderate (50% versus 50%) and severe (31% versus 18%, p = 0.4) disease as commonly as other patients. The frequencies of the DR antigens were similar in each category of disease severity. Patients with autoimmune features differed from patients without these features (3% versus 32%, p = 0.002) and normal subjects (3% versus 25%, p = 0.003) by having a lower frequency of HLA DR1.
  
  
  CONCLUSIONS
  The DR antigens are not associated with any index of disease severity at presentation. Immunologic manifestations do not identify patients with a different disease severity or a distinctive genetic predisposition for disease activity. The presence of DR 1 is associated with a lower frequency of immune manifestations.
authors.affiliation: Division of Gastroenterology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Czaja
authors.forename: H
authors.initials: H
authors.lastname: Carpenter
authors.forename: P J
authors.initials: PJ
authors.lastname: Santrach
authors.forename: S B
authors.initials: SB
authors.lastname: Moore
mesh_terms: D000974:Antibodies, Antinuclear / Q000276:immunology; D001219:Aspartate Aminotransferases / Q000097:blood; D001706:Biopsy; D002908:Chronic Disease; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006684:HLA-DR Antigens / Q000276:immunology*; D006526:Hepatitis C / Q000097:blood / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D012150:Polymorphism, Restriction Fragment Length; D012720:Severity of Illness Index; D005719:gamma-Globulins / Q000378:metabolism
chemical_list: D000974:Antibodies, Antinuclear; D006684:HLA-DR Antigens; D007074:Immunoglobulin G; D005719:gamma-Globulins; D001219:Aspartate Aminotransferases